Related Experiment Videos
Primary mucinous cystadenocarcinoma of the appendix with pseudomyxoma peritonei manifested as a splenic mass
P D Holder1, K M Fehir, M R Schwartz
1Department of Medicine, Pathology, Baylor College of Medicine, Houston, Tex.
Abstract:
We have reported a case of pseudomyxoma peritonei manifested as a splenic mass in a 38-year-old woman. Upon reviewing previously reported cases of pseudomyxoma peritonei with visceral involvement or extension above the diaphragm, we conclude that such spread of the disease does not significantly alter the prognosis. Furthermore, our findings support the concept that pseudomyxoma peritonei represents the implantation of malignant cells rather than metaplastic transformation of mesothelial cells.
Insights
Pseudomyxoma peritonei can present as a splenic mass. The spread of this rare cancer, even above the diaphragm, does not significantly impact patient prognosis and supports malignant cell implantation.
Area of Science:
- Oncology
- Pathology
Background:
- Pseudomyxoma peritonei (PMP) is a rare clinical condition characterized by mucinous ascites and tumor implants.
- The origin and behavior of PMP, particularly concerning visceral involvement and diaphragmatic extension, remain areas of ongoing research.
Observation:
- A case of PMP manifested as a splenic mass in a 38-year-old woman was documented.
- Review of existing literature on PMP with visceral involvement or supradiaphragmatic spread was conducted.
Findings:
- The extent of PMP spread, including visceral involvement or extension above the diaphragm, does not significantly alter the overall prognosis.
- The findings support the theory that PMP arises from the implantation of malignant cells, rather than from metaplastic changes in mesothelial cells.
Implications:
- This study refines understanding of PMP behavior and prognosis, irrespective of disease spread.
- The results reinforce the neoplastic origin of PMP, guiding future research and therapeutic strategies.